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The regulation of insulin gene expression in pan-
creatic -cells is the result of the coordinate activ-
ity of specific combinations of transcription factors
assembled on different promoter elements. We in-
vestigated the involvement of the aristaless-re-
lated homeoprotein Alx3 in this process. We found
that Alx3 is coexpressed with insulin in pancreatic
islets, as well as in the -cell line MIN6, and it is
also present in glucagon- and somatostatin-ex-
pressing cells. Chromatin immunoprecipitation as-
says indicated that Alx3 present in MIN6 cells and
in mouse pancreatic islets occupies the promoter
of the mouse insulin genes. EMSAs indicated that
Alx3 present in MIN6 cells binds to the A3/4 regu-
latory element of the insulin I promoter. We found
that Alx3 transactivates the insulin promoter by
acting on the E2A3/4 enhancer in conjunction with
the basic helix-loop-helix transcription factors
E47/Pan1 and Beta2/NeuroD, and that Alx3 physi-
cally interacts via the homeodomain with E47/Pan1
but not with Beta2/NeuroD. Alx3 binds to the A3/4
element as a dimer, and the homeodomain is suf-
ficient to recruit E47/Pan1 to the insulin promoter.
Deletion studies in transfected HeLa cells indi-
cated that proline-rich regions located at either
side of the Alx3 homeodomain work together with
E47/Pan1, and that this requires the integrity of the
amino-terminal activation domain to transactivate.
Thus, these studies support the notion that Alx3
participates in the regulation of insulin gene ex-
pression in pancreatic -cells. (Molecular Endo-
crinology 20: 2876–2889, 2006)
INSULIN IS AN essential hormone that regulates glu-cose homeostasis by acting on target organs such
as liver, muscle, and adipose tissue. Circulating insulin
is exclusively produced by the -cells of the islets of
Langerhans that constitute the endocrine compart-
ment of the pancreas. In addition to -cells, which
occupy most of the islet mass, the pancreatic islets
contain -cells that produce glucagon, -cells that
produce somatostatin, and cells that produce pancre-
atic polypeptide, all of these located in the islet pe-
riphery. The elucidation of the molecular mechanisms
by which these cell types are generated constitutes a
topic of intense study and has important implications
for our knowledge of the etiopathological processes
that lead to the occurrence of diabetes mellitus.
During development, the pancreatic bud is formed
from the primitive gut epithelium (1). The endocrine
cells that compose the islets derive from a subpopu-
lation of cells whose phenotypic fate is segregated
from that of exocrine cells by the expression of the
basic helix-loop-helix (bHLH) transcription factor neu-
rogenin-3 (2). From this point, the differentiation of
each islet cell type is regulated by the coordinated
expression of lineage-specific sets of transcription
factors. The expression of these sets is organized
hierarchically, so that each type of fully differentiated
islet cell ends up with a specific combination of tran-
scription factors that regulate the expression of target
genes characteristic of each one of the four cellular
phenotypes and are, therefore, important for the spec-
ification of their function (3, 4).
The promoter of the insulin gene contains several
DNA cis-regulatory elements that in -cells are coor-
dinately occupied by transcription factors that form
unique combinations typical of this type of pancreatic
islet cells (5). In this manner, insulin gene expression is
regulated with a high degree of cellular specificity that
restricts its expression to only one type of pancreatic
cells. Prominent among these elements due to their
critical importance for insulin gene expression are the
so called A- and E-boxes (6). A-boxes bind transcrip-
tion factors of the homeodomain family, whereas E-
boxes provide binding sites for bHLH proteins, such
as E47 (also known as Pan1) and Beta2/NeuroD. Ho-
meodomain and bHLH proteins synergistically en-
hance insulin transcription via direct protein-protein
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interactions (7–12). Also important for the regulation of
insulin gene expression in -cells are the paired-type
homeodomain transcription factor Pax6 (13) and the
basic leucine zipper protein MafA, which bind cis-
regulatory elements known as C-boxes (14–16).
Notably, studies carried out mostly in rodents have
demonstrated that many of the transcription factors
that regulate insulin gene expression are also required
for the proliferation of islet cell precursors and for the
differentiation and survival of -cells (17–19). In addi-
tion, the discovery of -cell transcription factors in
rodents has been highly predictive for the identifica-
tion of some causative aspects of human diabetes (18,
20–22), because mutations in the genes that encode
some of those transcription factors in humans are
associated with different types of diabetes (18, 20,
23–25). Therefore, knowing the complete spectrum of
transcription factors that operate in -cells has impor-
tant implications for the design of protocols to pro-
gram this type of cells as a putative tool to treat
diabetes.
Alx3 is a paired-class aristaless-like homeoprotein
expressed in different tissues during embryonic devel-
opment (26). Although a partial cDNA clone encoding
the Alx3 homeodomain was originally isolated from the
hamster insulinoma cell line HIT-T15 (27), the expres-
sion of Alx3 in pancreatic islets or the target genes that
it regulates have not been investigated. In the present
study, we present evidence in support of a role for Alx3
on the regulation of insulin gene expression in pancre-
atic -cells.
RESULTS
Alx3 Is Expressed in Pancreatic Islet Cells
The initial identification of Alx3 in hamster insulinoma
HIT-T15 cells (27) prompted us to investigate expres-
sion in pancreatic islet cells. Western immunoblot
showed that Alx3 is expressed in nuclear extracts of
the somatostatin-producing islet-derived RIN-
1027-B2 cell line, confirming our previous finding (28),
and of the insulin-producing -cell line MIN6 (Fig. 1A).
In contrast, we did not detect Alx3 expression in BHK-
21, COS-7, or HeLa cells (Figs. 1A and 4C). As a
positive control, we confirmed the presence of Alx3 in
RC2.E10 cells (Fig. 1A), a cell line derived from em-
bryonic rat neuroepithelium, that express Alx3 consti-
tutively (28). Nuclear localization of Alx3 was con-
firmed by immunocytochemistry in MIN6 and RIN-
1027-B2 cells (Fig. 1, B–E).
To test for expression of Alx3 in intact pancreatic
cells, we carried out immunohistochemistry on rat
pancreata. We found that Alx3 immunostaining is re-
stricted to islets, where Alx3-positive cells were found
distributed throughout the entire mass of the islets
(Fig. 2). Double-label immunohistochemistry demon-
strated that all -cells that synthesize insulin express
Alx3, and that Alx3-positive cells located in the periph-
ery of the islets correspond to glucagon- and soma-
tostatin-expressing cells (Fig. 2). Thus, Alx3 appears to
be present in all -, -, and -cells. In contrast, Alx3
immunoreactivity was not detected in the exocrine
pancreas (Fig. 2).
Alx3 Present in -Cells Recognizes the A3/4
Element of the Insulin Promoter
The expression of Alx3 in islet -cells suggested that
Alx3 may regulate insulin gene expression. To inves-
tigate whether Alx3 binds to the endogenous insulin
genes in intact cells, we carried out chromatin immu-
noprecipitation (ChIP) assays on the insulin-express-
ing islet -cell line MIN6, using a specific anti-Alx3
antiserum (28). We found that promoter sequences
from both insulin I and II genes were selectively am-
plified by PCR from chromatin immunoprecipitated
with the anti-Alx3 antiserum, but not with control pre-
immune serum (Fig. 3A). Promoter sequences from the
phosphoenolpyruvate carboxykinase (PCK) gene,
Fig. 1. Expression of Alx3 in Pancreatic Islet Cell Lines
A, Western immunoblots showing the presence of Alx3 in
nuclear extracts prepared from COS cells transfected with
pcDNA3-Alx3 (), from untransfected pancreatic islet-de-
rived MIN6 and RIN-1027-B2 cells, and from neural RC2.E10
cells, but not in extracts prepared from BHK-21 fibroblasts or
from COS cells transfected with pcDNA3 (). B–E, Immuno-
cytochemistry showing the presence of Alx3 immunoreactiv-
ity in nuclei of MIN6 (B) and RIN-1027-B2 (C) cells. In parallel
control experiments for MIN6 cells (D) and RIN-1027-B2 cells
(E), addition of the primary Alx3-specific antiserum was omit-
ted.
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used as a control, were not amplified from the anti-
Alx3 immunoprecipitated chromatin (Fig. 3A), indicat-
ing that Alx3 expressed in MIN6 -cells occupy the
endogenous insulin gene, but not the PCK gene. In
addition, we carried out ChIP assays on chromatin
prepared from mouse pancreatic islets, and we found
that a fragment of the insulin I gene was selectively
amplified by PCR with the anti-Alx3 antiserum, but not
with control preimmune serum (Fig. 3A), thus confirm-
ing that Alx3 is bound to the insulin gene promoter in
intact islets in vivo.
Next, we sought to identify regulatory elements rec-
ognized by Alx3. In the insulin I gene, at least two
important regulatory sites that incorporate TAAT se-
quence motifs recognized by homeodomain proteins,
that could serve as potential targets for binding by
Alx3, are present in the insulin promoter. Those regu-
latory sequences correspond to the A2 element, which
contains a single TAAT site, and the A3/4 elements,
which contain several TAAT sites (Fig. 3B). The A3/4
element forms a functional enhancer together with the
adjacently located E2 element, which binds bHLH pro-
teins (5). To determine whether Alx3 binds to any of those
sites, we carried out EMSA with synthetic oligonucleo-
tide probes using nuclear extracts from MIN6 cells.
When a probe corresponding to the A3/4 element
was used, several DNA-protein complexes were
found, whose sequence specificity was determined by
competition with unlabeled A3/4 oligonucleotide
added in excess to the binding reaction. Addition of an
oligonucleotide of unrelated sequence failed to com-
pete (Fig. 3B). To investigate whether any of the com-
plexes observed contain Alx3, we carried out the pro-
tein extract-DNA binding reaction in the presence of
the anti-Alx3 antiserum. The addition of this antiserum
resulted in the disappearance of one of the upper
complexes bound to the A3/4 probe, and in the ap-
pearance of a supershifted band, whereas the addition
of preimmune serum did not disturb the band pattern
(Fig. 3C). The specificity of the electrophoretic mobility
supershift observed with the anti-Alx3 antiserum was
further confirmed by using the antiserum 253 (29, 30),
which specifically recognizes the homeodomain tran-
scription factor Pdx1 (also known as IDX1, IPF1, and
STF1), because the A3/4 enhancer is a known target
for regulation by this homeoprotein (10, 31). Thus,
when EMSAs were carried out in the presence of the
anti-Pdx1 antiserum, we observed the disappearance
of one of the lower complexes bound to the A3/4
probe and the appearance of a supershifted band. The
upper complex affected by the anti-Alx3 antiserum
was unaffected by the anti-Pdx1 antiserum (Fig. 3B).
When we used the A2 probe, only a single protein-
DNA complex was identified. However, we found that
this complex contains Pdx1, but not Alx3, as a major
protein component, because it specifically disap-
peared in the presence of the anti-Pdx1 antiserum but
was unaffected by the anti-Alx3 antiserum (Fig. 3D).
Thus, these data demonstrate that Alx3 present in
MIN6  cells is able to recognize the insulin promoter
by binding specifically to the A3/4 element.
Alx3 Transactivates the Insulin Promoter
To investigate whether Alx3 exhibits insulin promoter
transactivation activity, we cotransfected the -cell
Fig. 2. Immunohistochemical Detection of Alx3, Insulin, Glucagon, and Somatostatin in Rat Pancreatic Islets
Sections on the top panels were doubly stained for both Alx3 and insulin (Alx3-I), Alx3 and glucagon (Alx3-G) or Alx3 and
somatostatin (Alx3-S). Sections in the middle panels were stained only for insulin (Ins), glucagon (Gluc), or somatostatin (Som).
Insets indicated on each of these sections are shown at higher magnification on the bottom panels. Note the absence of
Alx3-immunoreactive cells in the exocrine pancreas surrounding the islet.
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line MIN6 with the insulin promoter reporter plasmid
INSCAT and with the Alx3 expression plasmid pcDNA-
Alx3. INSCAT activity in transfected MIN6 cells was
found to be relatively high, with values similar to those
observed by the control plasmid RSVCAT. In addition,
we found that cotransfection of INSCAT with pcDNA-
Alx3 did not increase INSCAT activity in these cells
(Fig. 4A). Similarly, we observed no increase in chlor-
amphenicol acetyltransferase (CAT) activity when IN-
SCAT was cotransfected in MIN6 cells with expression
plasmids encoding known transactivators of the insu-
lin gene such as the homeoprotein Pdx1, or the bHLH
proteins E47/Pan1 (32) or Beta2/NeuroD (7) (Fig. 4A).
Similar results were obtained when we used the -cell
line INS-1 (data not shown). Because other homeodo-
main transcription factors expressed in -cells regu-
late insulin gene expression in combination with bHLH
proteins synergistically (10, 11, 33), we investigated
whether Alx3 could transactivate the insulin promoter
in the presence of E47/Pan1 and Beta2/NeuroD. We
found that cotransfection of INSCAT with expression
vectors for E47/Pan1 and/or Beta2/NeuroD did not
result in enhanced CAT activity in MIN6 cells. How-
ever, INSCAT activity increased 2- to 3-fold when an
expression vector for Alx3 was combined with both
E47/Pan1 and Beta2/NeuroD expression plasmids
(Fig. 4A).
Because MIN6 cells exhibit features of a well-differ-
entiated -cell phenotype (34), the relatively poor
magnitude of this response was interpreted as reflect-
ing the existence of near saturating levels of endoge-
nous Alx3 and of other -cell-enriched transcription
factors that regulate insulin gene expression (such as
Pdx1 and Beta2/NeuroD), and to the possible exis-
tence of limiting amounts of transcriptional coactiva-
tors such as cAMP response element binding protein-
binding protein (CBP)/p300, which is known to interact
with them (35). In support of this notion, we found that
INSCAT activity was increased 3-fold by cotransfec-
tion with an expression vector encoding the coactiva-
tor CBP (36) (Fig. 4B). We also observed that, although
Alx3 had no effect on its own, it was able to stimulate
INSCAT activity in the presence of CBP by approxi-
mately 2-fold relative to the activity elicited by CBP
alone, and 5- to 6-fold relative to basal INSCAT activity
(Fig. 4B).
Thus, to minimize interferences with endogenous
Alx3 that may regulate insulin gene expression in
-cells, we used HeLa cells in subsequent experi-
ments, because they do not express -cell-specific
transcription factors and we determined that they do
not contain detectable levels of Alx3 (Fig. 4C). In HeLa
cells, cotransfection of INSCAT with either Alx3 or
Pdx1 expression vectors did not result in elevated CAT
activity unless an E47/Pan1 expression vector was
added, in which case CAT activity was very signifi-
cantly elevated (Fig. 4D). These results are in agree-
ment with previous studies indicating that homeodo-
main and bHLH proteins cooperate to regulate insulin
gene expression (10, 11, 33), and suggest the exis-
tence of functional interactions between Alx3 and
E47/Pan1.
Because the E2A3/4 enhancer provides a major site
for synergistic interactions between bHLH and home-
Fig. 3. Binding of Alx3 to the Insulin Gene Promoter
A, ChIP assay showing PCR amplification in insulin chro-
matin immunoprecipitated (IP) from MIN6 cells (left panel) or
from mouse pancreatic islets (right panel) with an anti-Alx3
antiserum or with control nonimmune rabbit serum (NRS).
PCR amplification was not obtained with primers corre-
sponding to the control PCK gene. B and C, EMSAs showing
that Alx3 present in nuclear extracts of MIN6 cells binds to
the insulin I gene A3/4 site (C), but not to the A2 site (D),
whereas Pdx1 binds both to the A3/4 (B) and A2 (D) sites.
Oligonucleotide probes used in each assay are indicated at
the bottom of each panel. In B, nuclear extracts were incu-
bated in the absence () or presence of competing oligonu-
cleotides [10- or 100-fold molar excess (10, or 100, re-
spectively)] of identical probe sequence, or in the presence of
a nonspecific competing (NSC) oligonucleotide without TAAT
motifs used in a 100-fold molar excess. Arrows indicate the
supershifted (SS) band and the bands corresponding to the
complexes containing Alx3 or Pdx1. Addition of the anti-Pdx1
antiserum to the binding reaction with the A2 probe resulted
in disruption of the protein-DNA complex, whereas the anti-
Alx3 antiserum had no effect on this probe (D). Antisera
against Alx3 or Pdx1, or control nonimmune rabbit sera (NRS)
were added to the binding reactions 15 min before the ad-
dition of the probes. E, Schematic depiction of the promoter
of the rat insulin I gene showing the relative location of the
TAAT-containing A elements recognized by homeodomain
proteins. E boxes recognized by bHLH protein are also indi-
cated.
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odomain proteins (5), we tested the relative transacti-
vational activity of Alx3, alone or in combination with
E47/Pan1 or Beta2/NeuroD, in directing transcription
from this enhancer. For this purpose, we carried out
transfections in HeLa cells using the reporter plasmid
5FF-CAT, which bears five multimerized copies of the
rat insulin I E2A3/4 enhancer (37). We found that 5FF-
CAT activity in transfected HeLa cells was not in-
creased by Alx3 or E47/Pan1, but Beta2/NeuroD elic-
ited a small increase that was slightly potentiated in
the presence of E47/Pan1 (Fig. 4E). However, we ob-
served that, although Alx3 lacks transcriptional trans-
activation activity on its own, it was able to induce
transcription from 5FF-CAT in the presence of E47/
Pan1 or NeuroD/Beta2, an effect that further increased
significantly when both E47/Pan1 and NeuroD/Beta2
were present at the same time together with Alx3 (Fig.
4E). Thus, these experiments show that Alx3 exerts a
synergistic activation of the insulin gene promoter in
the presence of bHLH proteins expressed in -cells.
Together with the results from the EMSA experiments
described above, these experiments indicate that Alx3
directs transcription of the insulin gene by binding to
the E2A3/4 enhancer.
Alx3 Interacts with E47 But Not with
Beta2/NeuroD
The synergistic effects observed in the transfection
assays prompted us to investigate the possible exis-
tence of direct protein-protein interactions between
Alx3 and E47/Pan1 and/or Beta2/NeuroD, using glu-
tathione S-transferase (GST) pull-down assays. We
found that a GST-Alx3 fusion protein is able to interact
with [35S]Met-labeled E47/Pan1, but not with
[35S]Met-labeled Beta2/NeuroD (Fig. 5A). Because
E47/Pan1 and Beta2/NeuroD are known to act as part-
ners to form heterodimers, we used GST-E47 as a
positive control to confirm the ability of Beta2/NeuroD
to interact (Fig. 5A).
These data indicate that Beta2/NeuroD is unable to
interact with Alx3. However, our transfection experi-
ments in HeLa cells indicate the existence of a syner-
Fig. 4. Alx3 Transactivates the Insulin Promoter in Transfected Cells
A and B, Relative levels of CAT activity elicited in MIN6 cells cotransfected with the reporter plasmid INSCAT and expression
plasmids encoding the indicated transcription factors or the coactivator CBP. In B, the numbers below each column represent
the amount (in micrograms) of expression vectors used. C, Western immunoblot carried out with the anti-Alx3 antiserum
demonstrating expression of Alx3 in nuclear extracts from HeLa cells transfected with pcDNA3-Alx3 but not in those transected
with empty pcDNA3. D and E, Relative levels of CAT activity elicited in HeLa cells cotransfected with the reporter plasmid INSCAT
(D) or 5FFCAT (E) and expression plasmids encoding the indicated transcription factors. In all cases, the total amount of
transfected DNA was kept constant by adding the corresponding empty vector. Values represent the mean SEM of at least three
experiments carried out in duplicate.
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gistic increase in CAT activity when Beta2/NeuroD,
E47/Pan1, and Alx3 expression plasmids are cotrans-
fected together with the reporter plasmid 5FF-CAT
(see Fig. 4C). Thus, it is possible that the functional
interaction between Beta2/NeuroD and Alx3 is indirect
using E47/Pan1 as a bridging protein interacting both
with Beta2/NeuroD and with Alx3. To test this notion,
we carried out additional GST pull-down experiments
using a GST-Alx3 fusion protein and [35S]Met-labeled
Beta2/NeuroD, in the presence or absence of unla-
beled E47/Pan1 synthesized in vitro in a rabbit reticu-
locyte lysate system. The detection of a band corre-
sponding to Beta2/NeuroD only when E47/Pan1 was
present in the binding reaction (Fig. 5B) indicates the
formation of a trimeric complex and confirms that Be-
ta2/NeuroD interacts indirectly with Alx3 via direct
contact with E47/Pan1.
The occurrence of direct interactions between Alx3
and E47/Pan1 in  cells in vivo was tested by immu-
noprecipitation from MIN6 cell nuclei using the Alx3
antiserum, followed by Western immunoblot with a
specific anti-E47/Pan1 monoclonal antibody. The de-
tection of a band corresponding to E47/Pan1 in sam-
ples immunoprecipitated with the anti-Alx3 antiserum,
but not in those immunoprecipitated with nonimmune
rabbit serum (Fig. 5C), confirmed the Alx3-E47/Pan1
interaction in the nuclei of cells.
Besides the homeodomain, Alx3 contains three pro-
line-rich domains (28), two of them (Pro1 and Pro2)
located in the amino-terminal region and one (Pro3)
located in the carboxyl-terminal region (Fig. 5D). To
determine whether these domains are important for
the interactions with E47/Pan1, we carried out GST
pull-down assays using a GST-E47/Pan1 fusion pro-
tein and either full-length or truncated versions of
[35S]Met-labeled Alx3 generated by deletion of resi-
dues spanning either the carboxyl or the amino termi-
nus of Alx3. As shown in Fig. 5E, full-length Alx3 is able
to interact with GST-E47/Pan1. Increasing deletions of
either the amino (Alx357, Alx391, and Alx3143) or the
Fig. 5. Alx3 Physically Interacts with E47/Pan1 But Not with Beta2/NeuroD
A and B, GST pull-down assays showing selective interactions of Alx3 with E47/Pan1 but not with Beta2/NeuroD. 35S-labeled
in vitro-translated full-length E47/Pan1 or Beta2/NeuroD were incubated with the indicated purified GST fusion proteins ex-
pressed in bacteria and bound to glutathione-Sepharose beads. A, E47/Pan1 interacts with GST-Alx3, but not with control GST,
whereas Beta2/NeuroD interacts with GST-E47 but not with GST-Alx3. B, Beta2/NeuroD indirectly interacts with GST-Alx3 only
when unlabeled E47/Pan1 is present, indicating the formation of a ternary complex composed of GST-Alx3, unlabeled E47/Pan1,
and labeled Beta2/NeuroD. C, Interaction between Alx3 and E47/Pan1 in the nuclei of intact cells. Shown is a Western immunoblot
carried out with the anti-E47 antibody on samples that had been prepared by immunoprecipitation from MIN6 cell nuclear lysates
with either anti-Alx3 antiserum or control nonimmune rabbit serum (NRS). The asterisk denotes the presence of bands corre-
sponding to the immunoglobulins from the immunoprecipitation step. Input indicates a Western immunoblot carried out on MIN6
nuclear proteins not subjected to immunoprecipitation. D, Schematic depiction of the truncated versions of Alx3 used in the GST
pull-down experiments reported in D and E. Proline-rich domains (Pro1, Pro2, and Pro3) are indicated as striped boxes, and the
homeodomain (HD) as a black box. E, Purified GST-E47 was incubated with truncated versions of 35S-labeled, in vitro-translated
Alx3. Full-length Alx3 (Alx3FL), N-terminal deletions to amino acids 57 (Alx357), 91 (Alx391), or 143 (Alx3143), or C-terminal deletions
from amino acids 228 (Alx31–228) or 279 (Alx31–279) were used. Labeled products did not bind to control GST (data not shown).
F, Binding of 35S-labeled, in vitro-translated Alx3143–228 to GST-E47 but not to control GST. In this case, the labeled Alx3143–228
polypeptide was resolved in a 20% polyacrylamide gel.
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carboxyl terminus of Alx3 (Alx31–228 and Alx31–279),
but leaving intact the homeodomain, did not affect
dimerization with the GST-E47/Pan1 fusion protein
(Fig. 5E). Dimerization was also observed using la-
beled Alx3143–228, which corresponds to the Alx3 ho-
meodomain (Fig. 5F). In addition, none of the labeled
versions of Alx3 was observed to bind to control GST.
Thus, these experiments indicate that the segment of
Alx3 corresponding to the homeodomain is sufficient
for heterodimerization with E47/Pan1.
The Homeodomain of Alx3 Promotes Binding of
E47/Pan1 to the E2A3/4 Enhancer
To evaluate directly the binding of Alx3 and E47/Pan1
to the insulin promoter, we carried out EMSA. Because
we have previously determined that deletions of seg-
ments of the amino or carboxyl terminus of Alx3 do not
affect binding to DNA as long as the homeodomain
remains intact (28), we used Alx3143 or Alx3143–228
synthesized in reticulocyte lysates to better resolve the
protein-DNA complexes.
It is known that aristaless-like homeoproteins form
dimers cooperatively upon binding to DNA consensus
sequences known as P3 sites, which contain two in-
verted TAAT motifs separated by three nucleotides
(28, 38, 39). In addition, Alx3 binds selectively as a
monomer to specific TAAT-containing DNA se-
quences such as the GFAPT3 site found in the pro-
moter of the glial fibrillary acidic protein gene (28).
We found that Alx3143 binds to the E2A3/4 probe
forming two complexes (Fig. 6B), thus resembling the
binding pattern generated by the cooperative dimeriza-
tion observed upon binding to P3 sites (28). Indeed, a
comparison with the binding obtained with a GFAPT3
probe demonstrated that the lower complex corre-
sponds to the monomeric form of Alx3 bound to DNA
(Fig. 6B).
On the other hand, consistent with previous reports
(7, 10, 11), we found that E47/Pan1, but not Beta2/
NeuroD, can bind to the E2A3/4 probe (data not
shown). We then carried out titration experiments to
calculate the minimum amount of E47/Pan1 to detect
binding to the E2A3/4 probe, and investigated whether
E47/Pan1 can bind cooperatively with Alx3 to this site.
E47/Pan1 was used at a concentration that did not
yield appreciable binding to the E2A3/4 probe when
used alone.
When E47/Pan1 was incubated simultaneously with
Alx3143, the two complexes corresponding to the mo-
nomeric and dimeric forms of Alx3 were observed
unaltered (Fig. 6C). In addition, a band with lower
electrophoretic mobility appeared, an effect that was
not observed when Beta2/NeuroD was used instead of
E47/Pan1 (Fig. 6C). A similar effect was found when
we used Alx3143–228, which only spans the Alx3 ho-
meodomain (Fig. 6D). These results indicate that Alx3
and E47/Pan1 can interact cooperatively forming a
ternary complex on the DNA, and that the homeodo-
main of Alx3 is sufficient for the occurrence of this
interaction.
The Homeodomain of Alx3 Is Sufficient to
Promote E47/Pan1-Dependent Transactivation
In earlier studies, using promoter elements on which
Alx3 transactivation activity does not depend on direct
interactions with bHLH proteins, we found that Pro1
and Pro2 domains are necessary for transactivation,
but Pro3 is dispensable, and that the region spanning
the homeodomain is unable to transactivate on is own
(28). Thus, we tested for the relative contributions of
these domains to the transcriptional activity of Alx3
Fig. 6. EMSAs Showing Binding of Alx3 to Probes Corre-
sponding to the Insulin A3/4 Site Alone or Together with the
E2 Site, or to the Glial Fibrillary Acidic Protein T3 Element
(GFAPT3) Used as a Control for Monomeric Binding of Alx3
A, The sequences of the probes used are depicted. The
P3-like motif within the insulin A3/4 element is underlined. B,
The indicated amounts of reticulocyte lysates (0.5–4 l) con-
taining Alx3143 were incubated with the E2A3/4 or GFAPT3
probes. Note the formation of Alx3 predominantly as a dimer
(D) on the E2A3/4 probe compared with the monomer (M)
bound to the GFAPT3 probe. C, Demonstration of coopera-
tive binding of E47/Pan1 in the presence of Alx3 bound to the
E2A3/4 probe. Arrow indicates the generation of a complex
containing E47/Pan1 in the presence of Alx3143. D, A similar
experiment to the one depicted in B, but using Alx3143–228,
which corresponds to the homeodomain.
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from the insulin promoter, which depends on interac-
tions with E47/Pan1. For this purpose, we cotrans-
fected HeLa cells with the 5FF-CAT reporter plasmid
and expression plasmids encoding E47/Pan1 or trun-
cated versions of Alx3 lacking the amino-terminal or
the carboxyl-terminal domains.
As mentioned earlier, Alx3 is unable to transactivate
the 5FF-CAT reporter unless E47/Pan1 is present (see
Fig. 4E). In these experiments, we found that when
residues 1–143 of Alx3 were deleted (Alx3143), elimi-
nating the entire amino-terminal region to a position
next to the homeodomain, the CAT activity elicited by
both proteins was reduced to approximately 80% of
that obtained with the full-length proteins, indicating
that the Pro1 and Pro2 domains of Alx3 are not es-
sential for transactivation in the presence of E47/Pan1
(Fig. 7A). To test whether the Pro3 domain located in
the C-terminal region of Alx3 is essential for transac-
tivation, we cotransfected an expression vector en-
coding a truncated version of Alx3 spanning residues
1–228 (Alx31–228), in which the Pro1 and Pro2 do-
mains, as well as the homeodomain, remain intact. We
found that Alx31–228 yields levels of CAT activity that
are also about 80% of that obtained with full-length
Alx3 in the presence of E47/Pan1, indicating that the
Pro3 domain is not essential for activity when the other
two domains are intact (Fig. 7A). Finally, we cotrans-
fected an expression vector encoding Alx3143–228, a
truncated Alx3 protein in which both the amino- and
the carboxyl-terminal regions were deleted leaving in-
tact the homeodomain. We found that the activity elic-
ited by Alx3143–228 is about 20% of that elicited by
full-length Alx3 (Fig. 7A).
Interestingly, although greatly reduced, this is still a
significant degree of activity compared with back-
ground levels of 5FF-CAT activity, which are not in-
creased when either E47/Pan1 of Alx3 are transfected
alone (Figs. 4E and 7B). Because our previous work
demonstrated that the isolated Alx3 homeodomain lacks
transcriptional transactivation activity (28), these experi-
ments suggest that the residual activity observed when
Alx3143–228 and E47/Pan1 are present together is due to
the activity of the E47/Pan1 interacting with the Alx3
homeodomain at the insulin promoter.
To test this notion, we cotransfected the 5FF-CAT
reporter plasmid with expression vectors encoding the
Alx3 homeodomain (Alx3143–228) and with expression
vectors encoding truncated versions of E47/Pan1 corre-
sponding to amino-terminal deletions to residues 91,
334, or 549, that lack one or two of the activation do-
mains, but leave intact the bHLH domain (Fig. 7B). Co-
transfection of these plasmids with the plasmid encoding
Alx3143–228 resulted in the generation of background lev-
els of CAT activity indistinguishable from those observed
when Alx3143–228 was transfected alone. Thus, as pre-
dicted, stimulation of 5FF-CAT activity in the presence of
the Alx3 homeodomain was dependent on the integrity
of the transactivation domains of E47/Pan1.
In summary, all of these experiments taken together
support the notion that the Alx3 homeodomain inter-
acts with E47/Pan1 on the insulin promoter, and that
full transcriptional transactivation is contributed by
Alx3 proline-rich domains and E47/Pan1 transactiva-
tion domains, as well as by Beta2/NeuroD complexed
with E47/Pan1.
Fig. 7. Functional Interactions between the Homeodomain of Alx3 and E47/Pan1 in Transfected Cells
A, Relative CAT activities elicited in HeLa cells cotransfected with the 5FF-CAT reporter plasmid, an expression vector en
coding E47/Pan1, and expression vectors encoding either full-length (FL) or truncated versions of Alx3, as indicated schematically
on top. B, Relative CAT activities elicited in HeLa cells cotransfected with the 5FF-CAT reporter plasmid, an expression vector
encoding the Alx3 homeodomain (Alx3143–228), and expression vectors encoding either full-length (FL) or truncated versions of
E47/Pan1, as indicated schematically on top. In all cases, the total amount of transfected DNA was kept constant by adding the
corresponding empty vector. Values represent the mean  SEM of at least three experiments carried out in duplicate. HD,
Homeodomain; AD1 and AD2, activation domains 1 and 2; HLH, helix-loop-helix domain.
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DISCUSSION
Several studies using mice carrying mutant alleles
have advanced significantly our knowledge on the
functions of different aristaless-like genes, including
Cart1, Alx3, and Alx4, during embryonic development
(38, 40–44). However, despite these advances on the
developmental functions of aristaless-like transcription
factors, target genes regulated by them have not been
identified, and their functions as transcriptional regu-
lators of gene expression in differentiated cells remain
unknown.
In the present study, we have identified the insulin
gene as the first known target for regulation by Alx3.
This notion is based on the expression of Alx3 in
pancreatic islet cells, on DNA binding and ChIP assays
showing specific interactions of Alx3 with the insulin
promoter in -cells, and on functional transient trans-
fection assays showing that Alx3 transactivates the
insulin gene by interacting with bHLH proteins.
Alx3 Interacts with E47/Pan1 to Yield Synergistic
Transactivation of Insulin Gene Transcription
In addition to Alx3, the homeodomain proteins Pdx1
and Lim1.1 have been shown to interact with the class
A bHLH protein E47/Pan1 on the insulin E2A3/4 en-
hancer. In contrast, interactions with the class B bHLH
protein Beta2/NeuroD are selective, because only
Pdx1 appears to interact directly with Beta2/Neuro
(10). Our data indicate that the synergistic transacti-
vation observed between Alx3 and E47/Pan1 could be
due to interactions at two different levels. On the one
hand, direct protein-protein interactions with the Alx3
homeodomain bound to the E2A3/4 enhancer, bring-
ing in addition Beta2/NeuroD to the transcriptionally
active complex, and on the other hand functional in-
teractions of the transactivation domains, perhaps by
recruiting coactivator proteins that could not interact
stably with each factor in isolation.
Alx3 in pancreatic -cells recognizes the A3/4 site in
the promoter of the insulin gene. Although Alx3 binds
the A3/4 site preferentially as a dimer, a less intense
complex corresponding to the monomeric form was
also observed in EMSA carried out with the synthetic
version of the protein (see Fig. 6). The A3/4 element
contains the sequence TAATCTAATTA, which resem-
bles a P3 site to which paired class homeoproteins
bind preferentially as dimers in a cooperative manner
(28, 38, 39, 45). In addition, the palindromic motif
TAATTA within this sequence serves as a preferred
site for binding by Alx3 (28). Thus, these data suggest
that Alx3 dimerizes cooperatively upon binding to the
A3/4 site. In addition, the ability of Alx3 to interact
directly with E47/Pan1 appears to favor the coopera-
tive binding of this bHLH, which in turn would bring
Beta2/NeuroD to form a functionally active multipro-
tein complex assembled on the E2A3/4 enhancer.
Thus, these data reinforce the notion that synergistic
activation of the insulin promoter occurs as a conse-
quence of cooperative DNA binding that promotes
recruitment of multiple activators (10).
Functional interactions at the level of the transacti-
vation domains also appear to be important for syn-
ergistic enhancement of insulin transcription. We have
previously determined that the integrity of the Pro1
and Pro2 domains of Alx3 is required for transcrip-
tional transactivation from a generic P3 site, thus in-
dicating that the Pro3 domain is unable to function on
its own (28). However, in the present study, we have
observed that when Alx3 is acting from the E2A3/4
element in the presence of E47/Pan1, the Pro3 domain
is still able to synergize with this bHLH protein, whose
activity is in turn dependent on the integrity of the
transactivation AD1 domain. Interestingly, E47/Pan1 is
able to stimulate transcription, although relatively
weakly, when all the proline-rich domains of Alx3 have
been deleted, further supporting the notion that the
homeodomain of Alx3 is sufficient to recruit E47/Pan1
to a transcriptionally active complex assembled on the
insulin promoter. The mechanism by which the trans-
activation domains of Alx3 and bHLH proteins syner-
gize have not been explored in the present study, but
previous work (35) and our own data (see Fig. 4B)
suggest that interactions with coactivators such as
CBP/p300 may be involved.
Finally, it is possible that additional mechanisms
involving different types of proteins contribute to the
synergistic transactivation of Alx3 and E47/Pan1. For
example, recruitment of coactivators (37) or interac-
tions with HMG-type proteins have been shown to be
important in the case of the synergism between Pdx1
and E47/Pan1 (10). Also, it is possible that Alx3 can
alter chromatin conformation, as has been shown to
be the case for HNF1 (46), to favor the binding of
other transcription factors or coactivators. The study
of these possibilities remains the subject for future
research.
Regulation of Insulin Gene Transcription by Alx3
in Pancreatic -Cells
One important concept emerging from genetic studies
on aristaless-like genes is the existence of a relatively
high degree of functional redundancy among them
due to overlapping functions that only become evident
when double or triple mutant mice are generated (38,
43, 44). It is possible that redundancy also exists be-
tween Alx3 and other proteins that regulate the ex-
pression of the insulin gene in -cells, because Alx3
appears to function like other homeodomain transcrip-
tion factors that cooperate with bHLH proteins on the
E2A3/4 elements of the insulin promoter, such as Pdx1
or the LIM-domain proteins Lmx1.1 and Lmx1.2 (10,
11, 31, 47). However, ongoing studies in our laboratory
using Alx3 mutant mice (44) point to the existence of a
mild glucose homeostasis phenotype, lending support
to the notion that Alx3 participates in the control of
-cell function.
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Pdx1 has emerged as a major regulator of insulin
gene transcription in both humans and rodents (11,
48–50). However, although clearly important for -cell
function and survival, it appears that Pdx1 is not spe-
cifically required for insulin gene transcription, be-
cause insulin gene expression can occur in the ab-
sence of Pdx1 (17, 51, 52). These findings have been
interpreted on the basis that other homeodomain tran-
scription factors present in  cells can compensate for
the loss of Pdx1 by acting via a similar mechanism, i.e.
interaction with bHLH proteins at the level of specific
insulin promoter elements such as E2A3/4 (5). It is
possible that Alx3 could substitute for Pdx1, as the
LIM-homeodomain factors Lmx1.1 and Lmx1.2 may
also do (5). Thus, loss of a single homeodomain tran-
scription factor appears not sufficient to compromise
insulin gene transcription, because this is probably the
result of the coordinate activity of several of these
factors that can compensate for one another. In this
regard, studies aimed at determining functional inter-
actions between Alx3 and Pdx1 and their relative con-
tributions to regulation of insulin gene transcription are
currently being carried out in our laboratory.
As mentioned earlier, some of the functions of Alx3
and other aristaless-related genes have been identified
after generating mice with combined mutant alleles.
On the other hand, it has been shown that combined
heterozygous mutations in certain genes expressed in
-cells that have no effect on pancreatic function as
single mutants, such as Hnf1 or Hnf3, can lead to
altered -cell function resulting in decreased insulin
gene transcription or aggravation of diabetes caused
by haploinsufficiency of Pdx1 (53). Thus, although not
known at the present time, it is possible that mutations
in Alx3 in combination with mutations in other diabe-
tes-related genes may alter pancreatic -cell function
as a consequence of decreased insulin synthesis or
secretion. In this regard, it is important to note that
Alx3 is functionally related to Beta2/NeuroD, Pdx1,
and Hnf1, because it acts in combination with Beta2/
NeuroD (this study) and regulates insulin gene tran-
scription upon binding to the same promoter element
used by Pdx1 and Hnf1. These three genes are caus-
atively related to maturity onset diabetes of the young
(3). Further studies will determine whether mutations in
Alx3 are directly or indirectly related to the develop-
ment of diabetes.
MATERIALS AND METHODS
Cell Lines and Transfections
MIN6 cells (54) were cultured in the presence of 15% fetal
bovine serum and -mercaptoethanol (70 M), and were not
used after reaching 35 passages. INS-1E cells, provided by
Dr. Claes Wollheim (University of Geneva, Geneva, Switzer-
land) (55) were cultured in RPMI 1640 in the presence of 10%
fetal bovine serum, 1 mM sodium pyruvate, and 50 M -mer-
captoethanol. Neural RC2.E10 cells derive from cerebral cor-
tex of rat fetuses of 16 d of gestational age, and were cultured
at a temperature of 33 C as described (56). COS-7 (ATCC
CRL-1651; American Type Culture Collection, Manassas,
VA), HeLa cells, BHK-21 cells (baby hamster kidney fibro-
blasts) (ATCC CCL10), and rat pancreatic islet somatostatin-
producing RIN-1027-B2 cells (57) were cultured at a temper-
ature of 37 C. Unless otherwise stated, all cells were cultured
in DMEM containing 10% fetal bovine serum in the presence
of penicillin (100 U/ml) and streptomycin (10 g/ml). MIN6
cells were transfected with 5 g of reporter plasmid and 2 g
of expression plasmids using Lipofectin (Invitrogen Life
Technologies, San Diego, CA) as described (56). HeLa
cells were transfected with 10 g of reporter plasmid and
2 g of expression plasmids using the calcium phosphate
precipitation method. When necessary, total amount of
plasmid DNA was maintained constant by adding empty
expression vector.
CAT activity was measured by a solution assay (58) 48 h
after transfection exactly as described (56). Values were nor-
malized to those yielded by a Rous sarcoma virus enhancer
reporter plasmid (RSVCAT) transfected in parallel in MIN6
cells, or to CMVCAT in HeLa cells. All of the values are
expressed as mean  SEM of at least three independent
experiments carried out in duplicate.
Plasmids
INSCAT encodes a CAT reporter gene driven by a fragment
of the rat insulin I gene promoter spanning nucleotides 410
to 34 (59). 5FF-CAT is a reporter plasmid bearing five mul-
timerized copies of the rat insulin I E2A3/4 enhancer driving
CAT expression (provided by Dr. Melissa Thomas, Massa-
chusetts General Hospital, Boston, MA) (60). Construction of
the expression plasmids containing full-length and deleted
versions of Alx3 cloned into pcDNA3 has been described
(28). The plasmid pcDNA-Pdx1 contains a full-length cDNA
encoding rat IDX1 (61) cloned into the HindIII and NotI sites
of pcDNA3. The plasmid pCMV-Beta2 (provided by Dr. J.
Ferrer, Hospital Clinic, Barcelona, Spain) contains a full-
length cDNA encoding Beta2/NeuroD (7). The E47/Pan1 ex-
pression vector used in CAT reporter assays corresponds to
pCMV-Pan1 described by Nelson et al. (32).
For GST pull-down experiments and protein synthesis in
reticulocyte lysates, we used GST-E47, pcDNA3-E47, and
pcDNA3-Beta2 provided by Dr. Amparo Cano (Instituto de
Investigaciones Biome´dicas, Madrid, Spain) (62), as well as
GST-Alx3 and pcDNA3-Alx3 (full-length and deleted ver-
sions) previously described (28).
For experiments designed to test deleted versions of E47/
Pan1, we used the plasmid pZeoSV2 (Invitrogen Life Tech-
nologies, Carlsbad, CA) containing cDNAs encoding amino-
terminal deletions to residues 91, 334, or 549. These were
kindly provided by Dr. Amparo Cano (Instituto de Investiga-
ciones Biome´dicas, Madrid, Spain).
Western Immunoblot
Nuclear extracts from cells growing in 60-mm dishes were
prepared as described (63), and proteins were resolved by
SDS-PAGE and blotted onto a nitrocellulose membrane. Alx3
immunoreactivity was detected with a rabbit polyclonal pri-
mary antiserum (28) (1:5000 dilution), followed by incubation
with a goat antirabbit peroxidase-conjugated secondary an-
tibody (1:10,000 dilution) (Bio-Rad, Hercules, CA). Immuno-
reactive bands were visualized using an enhanced chemilu-
minescence detection system (ECL; Amersham Biosciences,
Piscataway, NJ).
Immunocytochemistry
Immunocytochemistry on MIN-6 and RIN-1027-B2 cells was
carried out basically as described (56). Cells plated into
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35-mm tissue culture dishes were fixed in 4% paraformalde-
hyde in PBS for 5 min, washed in PBS, and permeabilized
with methanol for 2 min at 20 C. After blocking with normal
goat serum for 1 h, cells were incubated overnight with the
anti-Alx3 antiserum (1:4000 dilution) at 4 C. Immunodetection
was carried out with a secondary biotinylated goat antirabbit
antiserum (Bio-Rad) using nickel-intensified immunoperoxi-
dase staining with a Vectastain ABC kit (Vector Laboratories,
Burlingame, CA).
Immunohistochemistry
Adult pancreata from Wistar rats (200–250 g body weight)
were fixed by transcardial perfusion with 4% paraformalde-
hyde, removed, postfixed overnight, and cryoprotected in
PBS containing 20% sucrose. Cryostat sections (20 m)
were cut and kept at80 C until used. Sections were brought
to room temperature, permeabilized with methanol for 2 min
at 20 C, treated with 5% normal goat serum, and then
incubated overnight with the anti-Alx3 (1:4000 dilution) anti-
serum at room temperature. Immunodetection was carried
out with a secondary biotinylated goat antirabbit antiserum
using nickel-intensified immunoperoxidase staining. For in-
sulin staining, sections were incubated with guinea pig anti-
human insulin (Linco Research, St. Charles, MO; 1:100 dilu-
tion), and immunodetection was carried out with a secondary
biotinylated goat anti-guinea pig antiserum using immuno-
peroxidase staining. For glucagon staining, we used a guinea
pig antibody (Linco Research; 1:100 dilution), detected with a
secondary biotinylated goat anti-guinea pig antiserum and
immunoperoxidase staining. For somatostatin staining, we
used a mouse monoclonal antibody (Acris Antibodies, Hid-
denhausen, Germany; 1:100 dilution), detected with a sec-
ondary biotinylated horse antimouse antiserum and immuno-
peroxidase staining.
For two-color dual antigen immunostaining, Alx3 was first
detected using nickel-enhanced immunostaining, which
yields a dark blue color. Sections were then washed, and
insulin, glucagon, or somatostatin immunohistochemistry
was carried as described above, using immunoperoxidase
staining without nickel, which yields a brown color.
Experimental protocols involving Wistar rats for the prep-
aration of sections for immunohistochemistry were approved
by the institutional committee on research animal care, and
meet the requirements of current Spanish and European
Community legislation.
EMSAs
EMSAs were carried out with either nuclear extracts (63) of
MIN-6 cells or with transcription factors synthesized in vitro
using a rabbit reticulocyte lysate system (Promega, Madison,
WI). Protease inhibitors (Complete protease inhibitor cocktail;
Roche, Basel, Switzerland) were added to nuclear extracts,
and protein concentrations were determined by the Bio-Rad
protein assay. Synthetic complementary oligonucleotides
with 5-GATC overhangs were annealed and labeled by a
fill-in reaction using [-32P]dATP and Klenow enzyme. Bind-
ing reactions were carried out in the presence of 20,000 cpm
of radiolabeled probe (6–10 fmol) in a total volume of 20 l
containing 2 g poly(dIdC), 20 mM HEPES (pH 7.9), 70 mM
KCl, 2.5 mM MgCl2, 1 mM dithiothreitol, 0.3 mM EDTA, and
10% glycerol. The sequences of the oligonucleotides used






ChIP assays were carried out basically as descried (64).
Cross-linked chromatin from mouse islets was generously
provided by Jorge Ferrer (Hospital Clinic, University of Bar-
celona, Barcelona, Spain). MIN6 cells were treated with 1%
formaldehyde for 15 min at room temperature and the cross-
linked protein-DNA complexes were isolated. After sonica-
tion, chromatin was incubated with anti-Alx3 antiserum or
control normal rabbit serum. Antibody-protein-DNA com-
plexes were isolated by incubation with protein A-Sepharose.
To detect bound DNA, PCR was carried out using oligonu-
cleotide primers that amplify a fragment of the mouse insulin
gene I spanning nucleotides 360 to 12. PCR conditions
were as follows: 95 C for 5 min, followed by 30 cycles of 94
C for 30 sec, 55 C for 30 sec, and 72 C for 30 sec, after which
a 5-min incubation at 72 C followed. The sequence of the
oligonucleotide primers are as follows: forward, 5-ATATT-
AGGTCCCTAACAACTGCAGT-3; and reverse, 5-TACTG-
GATGCCCACCAGCTTTATAG-3. To ensure specificity, the
3-end of the forward oligonucleotide corresponds to a 5-nu-
cleotide insertion absent in the insulin II gene. For amplifica-
tion of the mouse insulin II gene, we used the following
oligonucleotides: forward, 5-CAAAGATACTAGGTCCCCAA-
CTG-3; and reverse, 5-CCACTACCTTTATAGACCAAAGC-
3. PCR conditions were identical with those used for the
insulin I sequences. In this case, the 3 end of the forward
oligonucleotide corresponds to a 3-nucleotide insertion ab-
sent in the insulin I gene. In addition, specificity of the am-
plified fragments was checked by digestion with either AatII
or PstI, both of which only cut the fragment amplified from the
insulin II gene. As a control, we used promoter sequences
from the PCK gene (nucleotides 434 to 96) as indicated
by Cissell et al. (65). The sequence of the PCK oligonucleo-
tide primers are as follows: forward, 5-GAGTGACACCTCA-
CAGCTGTGG-3; and reverse, 5-GGCAGGCCTTTGGAT-
CATAGCC-3. PCR conditions were as follows: 95 C for 2
min, followed by 28 cycles of 95 C for 30 sec, 61 C for 30 sec,
and 72 C for 30 sec, after which a 5-min incubation at 72 C
followed.
In all cases, PCR products were run on a 1% agarose gel,
stained with ethidium bromide, and photographed.
GST Pull-Down Assays
Full-length or truncated versions of [35S]Met-labeled Alx3
were generated by in vitro translation using a rabbit reticulo-
cyte lysate system (Promega) and cDNAs cloned into
pcDNA3 (28). [35S]Met-labeled E47/Pan1 and Beta2/NeuroD
were similarly generated using plasmids pcDNA3-E47 and
pcDNA3-Beta2 (62). These labeled proteins were incubated
with recombinant GST-Alx3, GST-Alx3143–228 (28), or GST-
E47 (62) expressed in bacteria and bound to glutathione-
Sepharose beads (Amersham Biosciences, Little Chalfont,
UK). Incubations were carried out at 4 C for 1 h in buffer
containing 20 mM sodium phosphate (pH 7.9), 150 mM KCl,
0.5 mM EDTA, 0.02% Triton, 1 mM phenylmethylsulfonyl flu-
oride, and 2 g/ml aprotinin. After extensive washing, the
bead-bound proteins were denatured, resolved by SDS-
PAGE, and detected by autoradiography.
Immunoprecipitation
Nuclei from MIN6 cells (2  107) were prepared as de-
scribed by Schreiber et al. (63) by incubation of cells in
hypotonic buffer followed by vigorous agitation in the pres-
ence of 0.06% Igepal CA-630 (Sigma-Aldrich, St. Louis, MO).
Nuclei were then lysed in buffer containing 50 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 5 mM EDTA, 0.5% Igepal CA-630, and
protease inhibitor cocktail (Roche). Nuclear proteins were
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incubated overnight with either nonimmune rabbit serum or
with anti-Alx3 antiserum at 4 C, and then protein A-Sepha-
rose was added for another 2 h. After this, the samples were
centrifuged, washed, and resolved by SDS-PAGE. Proteins
were blotted onto a nitrocellulose membrane, and E47/Pan1
immunoreactivity was detected by Western immunoblot us-
ing a specific monoclonal antibody (BD Pharmingen, San
Diego, CA; 1:500 dilution).
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